KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Change in Receivables (2018 - 2025)

Historic Change in Receivables for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $536000.0.

  • Adaptive Biotechnologies' Change in Receivables fell 8970.02% to $536000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year decrease of 5837.06%. This contributed to the annual value of $3.7 million for FY2024, which is 28425.2% up from last year.
  • According to the latest figures from Q3 2025, Adaptive Biotechnologies' Change in Receivables is $536000.0, which was down 8970.02% from $702000.0 recorded in Q2 2025.
  • Over the past 5 years, Adaptive Biotechnologies' Change in Receivables peaked at $13.5 million during Q4 2022, and registered a low of -$9.1 million during Q1 2023.
  • Moreover, its 5-year median value for Change in Receivables was $1.2 million (2022), whereas its average is $1.8 million.
  • Per our database at Business Quant, Adaptive Biotechnologies' Change in Receivables skyrocketed by 460696.86% in 2022 and then crashed by 113236.71% in 2024.
  • Quarter analysis of 5 years shows Adaptive Biotechnologies' Change in Receivables stood at $287000.0 in 2021, then soared by 4606.97% to $13.5 million in 2022, then tumbled by 49.91% to $6.8 million in 2023, then plummeted by 86.71% to $899000.0 in 2024, then crashed by 40.38% to $536000.0 in 2025.
  • Its last three reported values are $536000.0 in Q3 2025, $702000.0 for Q2 2025, and $1.9 million during Q1 2025.